The "new therapy" aimed at treating Alzheimer's disease such as Alzheimer is accelerating the pace of development. Regarding head ultrasound therapy, the final clinical trials will be launched in Japan in 2022. Stem cell nerve regeneration technology also shows the possibility of obtaining treatment. Both therapeutic mechanisms of the two therapies are different from the United States Biogen and Japanese guards in 2021 to obtain conditional approval drugs in the United States. The goal is to achieve fundamental treatment.

The development of Alzheimer's ultrasonic therapy is Sound Wave Innovation, a startup from Northeast University in Japan. The method is to wear a dedicated equipment on the patient's head and expose a total of 1 hour with ultrasonic waves. 3 times a week for 1 course of treatment, repeated every 3 months.

The safety of this therapy has been confirmed in clinical trials from 2018 to 2019. In 2019, clinical trials were implemented with about 20 people, including mild Alzheimer's dementia patients and mild cognitive impairment (MCI) patients. Preliminary analysis shows that patients receiving the therapy have a tendency to deteriorate significantly. The clinical trial was planned to start the final stage with more patients in 2022. If the treatment effect is displayed, it is expected to obtain pharmaceutical approval in Japan in 2026.